Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 2.
FIG. 2.

GCCR ASO specifically reduced GCCR mRNA levels in liver and WAT from ZDF and HFD-STZ rats. Rats were dosed subcutaneously with saline (□), GCCR ASO 37.5 mg/kg (▪), or control ASO 37.5 mg/kg ([cjs2112]) twice a week for 4 weeks. Total mRNA was prepared from liver and WAT and analyzed for the expression of GCCR by RT-PCR (n = 8 per group for ZDF and n = 7 per group for HFD-STZ rats). Data are expressed as means ± SE relative to saline-treated rats. *P < 0.05, GCCR ASO treatment vs. saline treatment.

This Article

  1. Diabetes vol. 54 no. 6 1846-1853